HRT Financial’s Generate Biomedicines GENB Stock Holding History

HRT Financial’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-58,762	Closed	-$734K	–	5783
2026 Q1	$734K	Buy	+58,762	New	+$717K	﹤0.01%	2250

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HRT Financial's GENB Position: Q2 2026 in Review

HRT Financial sold out of Generate Biomedicines (GENB) in Q2 2026, closing a stake of 58,762 shares — an estimated $734K sold.

HRT Financial first reported a position in GENB in Q1 2026 and held it in 1 quarter. The position peaked at $734K in Q1 2026. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

HRT Financial reported no remaining Generate Biomedicines position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 58,762 Generate Biomedicines shares in Q2 2026, an estimated $734K.
HRT Financial first reported a position in Generate Biomedicines in Q1 2026 and held it in 1 quarter.
HRT Financial's Generate Biomedicines position peaked at $734K in Q1 2026.
86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.